Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Key Laboratory of Coronary Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Provincial Institute of Clinical Geriatrics, Fujian Provincial Key Laboratory of Geriatric Disease, Fujian Medical University, Fuzhou, China.
Sci Rep. 2017 Mar 24;7:45023. doi: 10.1038/srep45023.
Contrast-induced nephropathy (CIN) develops after the injection of iodinated contrast media. This is a post hoc analysis of the data obtained from the TRUST study, which was a prospective, multicentre, observational study conducted to evaluate the safety and tolerability of the contrast medium iopromide in patients undergoing cardiac catheterization from August 2010 to September 2011 in China, conducted to explore the current status, trends and risk predictors of hydration treatment. The status of hydration to prevent CIN in each patient was recorded. Of the total 17,139 patients from the TRUST study (mean age, 60.33 ± 10.38 years), the overall hydration usage was 46.1% in patients undergoing percutaneous coronary intervention (PCI) and 77.4%, 51.7%, and 48.5% in patients with pre-existing renal disease, diabetes mellitus, and hypertension, respectively. The proportion of hydration use increased from 36.5% to 55.5% from August 2010 to September 2011, which was independently associated with risk predictors like older age, pre-existing renal disease, hypertension, diabetes mellitus, prior myocardial infarction, ST segment elevation MI, high contrast dose, multi-vessel disease and reduced LVEF (<45%). Overall, the usage of intravenous hydration treatment for patients with a high risk of CIN following PCI was high in China.
对比剂肾病（CIN）在注射碘造影剂后发生。这是对 TRUST 研究数据的事后分析，该研究是一项前瞻性、多中心、观察性研究，旨在评估造影剂碘普罗胺在 2010 年 8 月至 2011 年 9 月期间在中国接受心脏导管检查的患者中的安全性和耐受性，旨在探讨水化治疗的现状、趋势和风险预测因素。记录了每位患者预防 CIN 的水化状态。在 TRUST 研究的 17139 例患者中（平均年龄 60.33±10.38 岁），接受经皮冠状动脉介入治疗（PCI）的患者水化使用率为 46.1%，而患有预先存在的肾脏疾病、糖尿病和高血压的患者的水化使用率分别为 77.4%、51.7%和 48.5%。从 2010 年 8 月至 2011 年 9 月，水化使用率从 36.5%增加到 55.5%，这与年龄较大、预先存在的肾脏疾病、高血压、糖尿病、先前的心肌梗死、ST 段抬高型心肌梗死、高对比剂量、多血管疾病和 LVEF（<45%）降低等风险预测因素独立相关。总体而言，中国 PCI 后 CIN 高危患者静脉水化治疗使用率较高。
